



## Copyright Transfer Agreement

The undersigned author (corresponding author) has submitted a manuscript entitled “Analisis Kejadian Leukositosis Pasca Terapi Aminofilin Intravena Dibandingkan dengan Salbutamol Nebulasi pada Pasien Eksaserbasi Asma” (the “Work”) which has been accepted for publication in *Jurnal Farmasi Klinik Indonesia*/Indonesian Journal of Clinical Pharmacy (IJCP).

- A. The author/authors transfer to *Jurnal Farmasi Klinik Indonesia*/Indonesian Journal of Clinical Pharmacy (IJCP) during the full term of copyright, the exclusive rights comprised in the copyright of the work, including but not limited to the right to publish the work and material contained therein throughout the world, in all languages and in all media of expression now known or later developed and to license or permit other to do so.
- B. Notwithstanding the above, the author/authors retains the following:
1. Proprietary rights other than copyright, such as patent rights.
  2. The right to make copies of all of part of the work for the author’s use in classroom teaching.
  3. The right to use all or part of the work in a book by the author, or a collection of the author’s work.
  4. The right to make copies of the work for internal distribution within the institution which employs the author.
  5. The right to use figures and tables of the work and up to 250 words of text, for any purpose.
  6. The rights to make oral presentations of material from the work.
  7. The right to include the work (post and preprint version) in an institutional repository.
- C. Author/authors agree that all copies made under any of the above conditions will include a notice of copyright and a citation to the publication.

March 12<sup>th</sup>, 2016

.....  
Corresponding Author’s signature

Amelia Lorensia

Fakultas Farmasi Universitas Surabaya  
Surabaya, Indonesia



KOMITE ETIK PENELITIAN KESEHATAN  
RUMKITAL Dr. RAMELAN  
SURABAYA

KETERANGAN KELAIKAN ETIK  
("ETHICAL CLEARANCE")

No. 01 /EC/KERS/2014

KOMITE ETIK PENELITIAN KESEHATAN RUMKITAL Dr. RAMELAN SURABAYA, TELAH MEMPELAJARI SECARA SEKSAMA RANCANGAN PENELITIAN YANG DIUSULKAN, MAKA DENGAN INI MENYATAKAN BAHWA PENELITIAN BERJUDUL :

Analisis Perbandingan Risiko dan Manfaat (Risk-Benefit Assessment) Penggunaan Aminofilin dan Salbutamol Pada Pasien dengan Eksaserbasi Asma.

PENELITI UTAMA :


Amelia Lorensia, S. Farm., M. Farm-Klin., Apt. ( Nim. 2009.04.0.0091 )

UNIT/LEMBAGA/TEMPAT PENELITIAN :

Rumkital Dr. Ramelan Surabaya.

**DINYATAKAN LAIK ETIK**

Surabaya, 28 Januari 2014

  
dr. Tarka Nandaka, Sp. KJ



PEMERINTAH KOTA SURABAYA  
**RSUD dr. MOHAMAD SOEWANDHIE**  
Jalan Tambak Rejo No. 45 - 47 Telp. : (031) 3717141, 3725905  
**SURABAYA**

Surabaya, 17 Pebruari 2014

Nomer : 070/2506/436.7.8/2014  
Sifat : -  
Lampiran : -  
Hal : Permohonan Ijin Penelitian

Yth.

KEPADA  
Dekan  
Fakultas Farmasi  
Universitas Surabaya  
Di -

**SURABAYA**

Menindak lanjuti surat dari Fakultas Farmasi Universitas Surabaya tanggal 03 September 2013 nomor : 1202/Dek/FF/IX/2013 perihal Permohonan Ijin Penelitian atas nama Amelia Lorensia, S.Farm., M.Farm-Klin., Apt. dengan judul "Analisis Perbandingan Risiko Dan Manfaat (*Risk-Benefit Assessment*) Penggunaan Aminofilin Dan Salbutamol Pada Pasien Dengan Eksaserbasi Asma" dengan ini kami beritahukan bahwa Instalasi Gawat Darurat (IGD), Instalasi Laboratorium dan Poli Paru RSUD Dokter Mohamad Soewandhie Surabaya **tidak keberatan** untuk penelitian dimaksud dengan mentaati peraturan yang berlaku.

Demikian pemberitahuan kami. Atas perhatian dan kerja samanya disampaikan terima kasih.

an. Plt. DIREKTUR  
WAKIL DIREKTUR UMUM & KEUANGAN

  
SHALIM KAMAJAYA, SE, MM  
Pembina  
NIP. 19580910 198502 1 001